Skip Navigation
Find a Doctor
 
 
 
 

 

Photo of Dr. Hiroshi Miyamoto, M.D., Ph.D.

Hiroshi Miyamoto, M.D., Ph.D.

Associate Professor of Pathology

Male  | Languages: English, Japanese

Main Location

The Johns Hopkins Hospital

Titles

  • Associate Professor of Pathology
  • Associate Professor of Urology

Centers & Institutes

Departments

  • Pathology - Kidney-Urologic Pathology
  • Urology

Locations

The Johns Hopkins Hospital

600 N. Wolfe Street
Sheikh Zayed Tower
Baltimore, MD 21287 map
Phone: 410-614-1442

Expertise

Pathology

Research Interests

Prostate cancer; Bladder cancer; Androgen receptor co-regulators; Androgen receptor signals; Steroid hormone receptors; Genitourinary pathology

Biography

Dr. Miyamoto is an associate professor of pathology and urology at the Johns Hopkins School of Medicine.

A specialist in genitourinary pathology, Dr. Miyamoto earned his medical degree and a PhD degree in medicine (urology) from Yokohama City University. He trained and completed his residency at Yokohama City University Hospital.

Dr. Miyamoto served as a hospital urologist in Japan before coming to the U.S.

Dr. Miyamoto completed an anatomic pathology residency at the University of Rochester Medical Center and a urological pathology clinical fellowship at The Johns Hopkins Hospital.

Dr. Miyamoto’s primary research interest is genitourinary pathology – particularly the molecular biology of steroid hormone receptors in genitourinary tumors.

Dr. Miyamoto has published more than 140 journal articles and book chapters related to his research and has served as a reviewer for publications in scores of journals.

Dr. Miyamoto also edited Gordo''s Guide to GU Pathology: A Resource for Urology and Pathology Residents.

...read more

    Additional Information

  • Education +

    Degrees

    • Yokohama City University / MD (1988)

    Residencies

    • Yokohama City University Hospital / Urology (1990)
    • University of Rochester Medical Center / Pathology (2008)

    Fellowships

    • Johns Hopkins University School of Medicine / Pathology (2009)

    Certifications

    • American Board of Pathology / Anatomic Pathology (2008)
  • Research & Publications +

    Research Summary

    Dr. Miyamoto’s primary research interest is genitourinary pathology—particularly the molecular biology of steroid hormone receptors in genitourinary tumors.

    His work includes studying the role of androgen receptor signals in bladder cancer development and progression; evaluating the efficacy of new androgen receptor antagonists in prostate cancer progression; and characterizing novel androgen receptor co-regulators in prostate cancer cells.

    Selected Publications

    1. Miyamoto H, Kubota Y, Shuin T, Torigoe S, Hosaka M, Iwasaki Y, Danenberg K, Danenberg PV. Analyses of p53 gene mutations in primary human bladder cancer. Oncol Res 1993;5(6-7):245-9.
    2. Miyamoto H, Shuin T, Torigoe S, Iwasaki Y, Kubota Y. Retinoblastoma gene mutations in primary human bladder cancer. Br J Cancer 1995 Apr;71(4):831-5.
    3. Miyamoto H, Kubota Y, Shuin T, Torigoe S, Dobashi Y, Hosaka M. Expression of transforming growth factor-beta 1 in human bladder cancer. Cancer 1995 May;75(10):2565-70.
    4. Miyamoto H, Kubota Y, Fujinami K, Dobashi Y, Kondo K, Yao M, Shuin T, Hosaka M. Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers. Oncol Res 1995;7(7-8):327-30.
    5. Miyamoto H, Shuin T, Ikeda I, Hosaka M, Kubota Y. Loss of heterozygosity at the p53, RB, DCC, and APC tumor suppressor gene loci in human bladder cancer. J Urol 1996 Apr;155(4):1444-7.
    6. Miyamoto H, Kubota Y, Shuin T, Shiozaki H. Bilateral adrenocortical carcinoma showing allelic losses at the p53 and RB gene loci. Cancer Genet Cytogenet 1996 Jun;88(2):181-3.
    7. Miyamoto H, Yeh S, Wilding G, Chang C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 1998 Jun;95(13):7379-84.
    8. Miyamoto H, Yeh S, Lardy H, Messing E, Chang C. Delta5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA 1998 Sep;95(19):11083-8.
    9. Miyamoto H, Miyagi Y, Ishikawa T, Ichikawa Y, Hosaka M, Kubota Y. DNA polymerase β gene mutation in human breast cancer. Int J Cancer 1999 Nov;83(5):708-9.
    10. Miyamoto H, Chang C. Antiandrogens fail to block androstenedione-mediated mutated androgen receptor transactivation in human prostate cancer cells. Int J Urol 2000 Jan;7(1):32-4.
    11. Miyamoto H, Kubota Y, Noguchi S, Takase K, Matsuzaki J, Moriyama M, Takebayashi S, Kitamura H, Hosaka M. c-erbB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 2000 May;55(5):679-83.
    12. Miyamoto H, Rahman M, Takatera H, Kang H-Y, Yeh S, Chang H-C, Nishimura K, Fujimoto N, Chang C. A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J Biol Chem 2002 Feb;277(7):4609-17.
    13. Miyamoto H, Marwah P, Marwah A, Lardy H, Chang C. 3β-Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. Proc Natl Acad Sci USA 2003 Apr;100(8):4440-4.
    14. Miyamoto H, Rahman MM, Chang C. Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem 2004 Jan;91(1):3-12.
    15. Miyamoto H, Messing EM. Early versus late hormonal therapy for prostate cancer. Curr Urol Rep 2004 Jun;5(3):188-96.
    16. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 2004 Dec;61(4):332-53.
    17. Miyamoto H, Messing EM, Chang C. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer? Nat Clin Pract Oncol 2005 May;2(5):236-7.
    18. Miyamoto H, Altuwaijri S, Cai Y, Messing EM, Chang C. Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: Potential therapeutic approaches for prostate cancer. Mol Carcinogen 2005 Sep;44(1):1-10.
    19. Miyamoto H, Marwah P, Marwah A, Yang Z, Chung C-Y, Altuwaijri S, Chang C, Lardy H. Identification of steroid derivatives that function as potent antiandrogens. Int J Cancer 2005 Dec;117(5):866-72.
    20. Yang Z, Chang Y-J, Yu I-C, Yeh S, Wu C-C, Miyamoto H, Merry DE, Sobue G, Chen L-M, Chang S-S, Chang C. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 2007 Mar;13(3) 348-53.
    21. Miyamoto H, Yang Z, Chen Y-T, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, Yeh S, Messing EM, Chang C. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 2007 Apr;99(7):558-68.
    22. Miyamoto H, Hernandez DJ, Epstein JI. A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy. Hum Pathol 2009 Dec;40(12):1693-8.
    23. Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI. Non-invasive papillary urothelial neoplasms: The 2004 WHO/ISUP classification system. Pathol Int 2010 Jan;60(1):1-8.
    24. Miyamoto H, Sharma RB, Illei PB, Epstein JI. Pitfalls in the use of smoothelin to identify muscularis propria invasion by urothelial carcinoma. Am J Surg Pathol 2010 Mar;34(3):418-22.
    25. Miyamoto H, Montgomery EA, Epstein JI. Paratesticular fibrous pseudotumor: A morphological and immunohistochemical study of 13 cases. Am J Surg Pathol 2010 Apr;34(4):569-74.
    26. Miyamoto H, Brimo F, Schultz L, Ye H, Miller JS, Fajardo DA, Lee TK, Epstein JI, Netto GJ. Low-grade papillary urothelial carcinoma of the urinary bladder: A clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center. Arch Pathol Lab Med 2010 Aug;134(8):1160-3.
    27. Miyamoto H, Epstein JI. Transurethral resection specimens of the bladder: Outcome of invasive urothelial cancer involving muscle bundles indeterminate between muscularis mucosae and muscularis propria. Urology 2010 Sep;76(3):600-4.
    28. Izumi K, Zheng Y, Miyamoto H. Eppin expression in prostate cancer. Eur Urol 2011 Jun;59(6):1071-2.
    29. Canacci AM, Izumi K, Zheng Y, Gordetsky J, Yao JL, Miyamoto H. Expression of semenogelins I and II and its prognostic significance in human prostate cancer. Prostate 2011 Jul;71(10):1108-14.
    30. Zheng Y, Izumi K, Yao JL, Miyamoto H. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocr Relat Cancer 2011 Jul;18(4):451-64.
    31. Gordetsky J, Findeis-Hosey J, Erturk E, Messing EM, Yao JL, Miyamoto H. Role of frozen section analysis of testicular/paratesticular fibrous pseudotumours: a five-case experience. Can Urol Assoc J 2011 Aug;5(4):E47-51.
    32. Miyamoto H, Zheng Y, Izumi K. Nuclear hormone receptor signals as new therapeutic targets for urothelial carcinoma. Curr Cancer Drug Tar 2012 Jan;12(1):14-22.
    33. Subik MK, Yao JL, di Sant’Agnese PA, Miyamoto H. The role of periprostatic and periseminal vesicle lymph node metastasis in the staging and prognosis of prostate cancer. Histopathology 2012 May;60(6):1009-10.
    34. Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, Netto GJ, Yeh S. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int 2012 Jun;109(11):1716-26.
    35. Li Y, Izumi K, Miyamoto H. The role of the androgen receptor in the development and progression of bladder cancer. Jpn J Clin Oncol 2012 Jul;42(7):569-77.
    36. Choy B, Gordetsky J, Miyamoto H. Clinicopathologic features of prostate cancer in patients diagnosed by age 45 who underwent radical prostatectomy. Eur Urol 2012 Aug;62(2):354-5.
    37. Subik MK, Gordetsky J, Yao JL, di Sant’Agnese PA, Miyamoto H. Frozen section assessment in testicular and paratesticular lesions suspicious for malignancy: its role in preventing unnecessary orchiectomy. Hum Pathol 2012 Sep;43(9):1514-9.
    38. Izumi K, Li Y, Zheng Y, Gordetsky J, Yao JL, Miyamoto H. Seminal plasma proteins in prostatic carcinoma: Increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy. Hum Pathol 2012 Nov;43(11):1991-2000.
    39. Miyamoto H, Izumi K, Yao JL, Li Y, Yang Q, McMahon LA, Gonzalez-Roibon N, Hicks DG, Tacha D, Netto GJ. GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor. Hum Pathol 2012 Nov;43(11):2033-40.
    40. Izumi K, Zheng Y, Li Y, Zaengle J, Miyamoto H. Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor. Int J Oncol 2012 Nov;41(5):1587-92.
    41. Zhao C, Venigalla S, Miyamoto H. Chronic inflammation on initial benign prostate biopsy is a negative predictor of subsequent cancer detection. Pathol Int 2012 Nov;62(11):774-6.
    42. Zheng Y, Izumi K, Li Y, Ishiguro H, Miyamoto H. Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasone-mediated glucocorticoid receptor signals. Mol Cancer Ther 2012 Dec;11(12):2621-32. doi: 10.1158/1535-7163.MCT-12-0621.
    43. Izumi K, Zheng Y, Hsu J-W, Chang C, Miyamoto H. Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: A potential mechanism of androgen-induced bladder carcinogenesis. Mol Carcinogen 2013 Feb;52(2):94-102. doi: 10.1002/mc.21833.
    44. Venigalla S, Zhao C, Miyamoto H. Histopathologic features of atypical glands on prostate biopsy: Nucleolar size is a predictor of subsequent detection of prostatic adenocarcinoma. Prostate 2013 Mar 73(4):376-81.
    45. Ishiguro Y, Ishiguro H, Miyamoto H. Epidermal growth factor receptor tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces subsequent development of interstitial pneumonia. Oncotarget 2013 Apr;4(4):550-9.
    46. Li Y, Zheng Y, Izumi K, Ishiguro H, Ye B, Li F, Miyamoto H. Androgen activates β-catenin signaling in bladder cancer cells. Endocr Relat Cancer 2013 May;20(3):293-304. doi: 10.1530/ERC-12-0328.
    47. Kakiuchi Y, Choy B, Gordetsky J, Izumi K, Wu G, Rashid H, Joseph JV, Miyamoto H. Role of frozen section analysis of surgical margins during robot-assisted laparoscopic radical prostatectomy: a 2,608-case experience. Hum Pathol 2013 Aug;44(8):1556-62.
    48. Venigalla S, Wu G, Miyamoto H. The impact of routine frozen section analysis during partial nephrectomy on surgical margin status and tumor recurrence: A clinicopathologic study of 433 cases. Clin Genitourin Cancer 2013 Dec;11(4):527-36.
    49. Kawahara T, Miyamoto H. Androgen receptor antagonists in the treatment of prostate cancer. Clin Immunol Endocr Metab Drugs 2014;1(1):11-9.
    50. Izumi K, Li Y, Ishiguro H, Zheng Y, Yao JL, Netto GJ, Miyamoto H. Expression of UDP-glucuronosyltransferase 1A in bladder cancer: association with prognosis and regulation by estrogen. Mol Carcinogen 2014 Apr;54(4):314-24.
    51. Li Y, Ishiguro H, Kawahara T, Kashiwagi E, Izumi K, Miyamoto H. Loss of GATA3 in bladder cancer promotes cell migration and invasion. Cancer Biol Ther 2014 Apr;15(4):428-35.
    52. Ishiguro H, Kawahara T, Zheng Y, Netto GJ, Miyamoto H. Reduced glucocorticoid receptor expression predicts bladder tumor recurrence and progression. Am J Clin Pathol 2014 Aug;142(2):157-64.
    53. Ishiguro H, Kawahara T, Zheng Y, Kashiwagi E, Li Y, Miyamoto H. Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity. Cancer Chemother Pharmacol 2014 Aug;74(2):249-55.
    54. Li Y, Ishiguro H, Kawahara T, Miyamoto Y, Izumi K, Miyamoto H. GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens. Am J Cancer Res 2014 Sep;4(5):461-73.
    55. Izumi K, Taguri M, Miyamoto H, et al. Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget 2014 Dec;5(24):12665-74.
    56. Kawahara T, Kashiwagi E, Ide H, Li Y, Zheng Y, Miyamoto Y, Netto GJ, Ishiguro H, Miyamoto H. Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1. Oncotarget, in press.
    57. KawaharaT, KashiwagiE, Ide H, Li Y, ZhengY, IshiguroH, Miyamoto H. The role of NFATc1 in prostate cancer progression: Cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion. Prostate, in press.
    58. Kawahara T, Kashiwagi E, Li Y, Zheng Y, Miyamoto Y, Netto GJ, Ishiguro H, Miyamoto H. Cyclosporine A and tacrolimus inhibit urothelial tumorigenesis. Mol Carcinogen, in press.
    59. Ishiguro H, Izumi K, Kashiwagi E, Zheng Y, Li Y, Kawahara T, Miyamoto H. Semenogelin I promotes prostate cancer cell growth via functioning as an androgen receptor coactivator and protecting against zinc cytotoxicity. Am J Cancer Res, in press.
  • Academic Affiliations & Courses +
  • Activities & Honors +

    Honors

    • Prostate Cancer Research Program Physician Research Training Award, Department of Defense , 2009
    • Support Award at the University of Rochester Medical Center, Clinical and Translational Science Institute Laboratory , 2012
    • Prostate Cancer Research Program Idea Development Award, Department of Defense , 2013
  • Videos & Media +
Is This You? Edit Profile
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.